Indications And Dose
HIV-1 infection (initiated by a specialist) ▶BY MOUTH ▶Adult: 50/25 mg once daily DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg dolutegravir/rilpivirine.
PDF page 701
Loading InternPractice…
Drug reference
HIV-1 infection (initiated by a specialist) ▶BY MOUTH ▶Adult: 50/25 mg once daily DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg dolutegravir/rilpivirine.
PDF page 701
Scottish Medicines Consortium (SMC) decisions SMC No. SMC2091 The Scottish Medicines Consortium has advised (September 2018) that dolutegravir with rilpivirine film-coated tablet (Juluca ®) is accepted for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV- 1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower. All Wales Medicines Strategy Group (AWMSG) decisions AWMSG No. 2850 The All Wales Medicines Strategy Group has advised (December 2018) that dolutegravir with rilpivirine (Juluca ®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/ml) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any nonnucleoside reverse transcriptase inhibitor or integrase inhibitor. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS Infection price.
PDF pages 701, 702
→Appendix 1: dolutegravir. rilpivirine
PDF page 701
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Juluca (ViiV Healthcare UK Ltd) A Rilpivirine (as Rilpivirine hydrochloride) 25 mg, Dolutegravir (as Dolutegravir sodium) 50 mg Juluca 50mg/25mg tablets | 30 tablet P £699.02
PDF page 702
Missed doses If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness and drowsiness.
PDF page 701
50/25 mg once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 701